Krystal Biotech focuses on gene-based dermatology treatments as investors watch long-term growth
Krystal Biotech Inc. is a biotechnology company specializing in gene-based therapies for rare and severe skin diseases, aiming to provide long-lasting treatment options. Listed on Nasdaq, the company focuses on localized gene delivery to the skin and targets conditions with well-defined genetic causes. Its long-term value is tied to clinical trial progress, regulatory interactions, and the successful development of its specialized dermatology pipeline.
Price to book forward of Krystal Biotech, Inc. – NASDAQ:KRYS
This article focuses on the "Price to book forward" financial metric for Krystal Biotech, Inc. (NASDAQ: KRYS). It appears to be a stub or a placeholder page from TradingView, providing financial market data and general information about the company's stock.
KRYS - Krystal Biotech Inc Options
This page provides an in-depth financial overview of Krystal Biotech Inc. (KRYS), including its latest stock performance, key financial metrics, insider and institutional ownership, and analyst recommendations. It details the company's market capitalization, income, sales, and various financial ratios, alongside its stock performance over different periods.
FDA PreCheck Could Speed Up These 3 U.S. Biopharma Stocks
The FDA's new PreCheck pilot program aims to accelerate facility reviews for biopharmaceutical manufacturers, potentially impacting the speed at which complex therapies reach the market. This article highlights three U.S. biopharma stocks—Krystal Biotech (KRYS), SpringWorks Therapeutics (SWTX), and IVERIC bio (ISEE)—that are positioned to benefit from this regulatory shift. Each company is analyzed for its current operations, market standing, and specific opportunities and risks in light of faster approval processes and manufacturing scale-up potential.
Krystal Biotech, Inc. (KRYS) Stock Analysis: A Biotech Marvel with 31.9% Revenue Growth and Strong Buy Ratings
Krystal Biotech, Inc. (KRYS) is highlighted as a formidable player in the biotechnology sector, boasting a market capitalization of $10.97 billion and a remarkable revenue growth rate of 31.90%. The company specializes in genetic medicines, with its flagship product VYJUVEK treating dystrophic epidermolysis bullosa (DEB), and maintains a robust pipeline for other medical challenges. Despite a potential downside against its average target price, analysts maintain an overwhelmingly bullish consensus, driven by strong financial performance and sustained upward market momentum.
Krystal Biotech, Inc. Actuals & Estimates (FWB:4KB)
This article provides an overview of Krystal Biotech, Inc. (FWB:4KB) stock, including its current price, performance, analyst forecasts, and financial data. It highlights the stock's recent price increase, its market capitalization, and upcoming earnings report, along with historical highs and lows.
Krystal Biotech EVP sells $347,270 in common stock By Investing.com
Thomas John Charles, EVP and General Counsel at Krystal Biotech, sold 1,000 shares of common stock for $347,270 after exercising stock options. This transaction was part of a pre-arranged 10b5-1 trading plan. The company recently reported strong Q1 2026 earnings, surpassing expectations, and received UK marketing authorization for its gene therapy VYJUVEK.
Form 4 Krystal Biotech Inc For: 26 June By Investing.com
This article announces the filing of a Form 4 for Krystal Biotech Inc. on June 26. It is a brief, one-sentence update provided by Investing.com, typical of regulatory filing notifications. The article includes standard market data and related news not specific to the Form 4.
Responsive Playbooks and the KRYS Inflection
This article from Stock Traders Daily discusses an inflection point for Krystal Biotech Inc. (NASDAQ: KRYS), noting strong sentiment across all horizons and a potential breakout. It provides AI-generated institutional trading strategies for long, momentum, and risk-hedging positions, along with multi-timeframe signal analysis for various holding periods. The report highlights compelling upside potential with no resistance levels remaining above the current price.
Krystal Biotech EVP sells $347,270 in common stock
Thomas John Charles, EVP and General Counsel at Krystal Biotech, Inc., sold 1,000 shares of common stock for $347,270 on June 25, 2026. This transaction followed the exercise of stock options for 1,000 shares at $179.25 per share, both executed under a Rule 10b5-1 trading plan. After the sale, Mr. Thomas holds no direct shares but retains 6,500 derivative shares.
Krystal Biotech (KRYS) EVP executes 10b5-1 option exercise and 1,000-share sale
Krystal Biotech's EVP and General Counsel, Thomas John Charles, exercised stock options for 1,000 shares at $179.25 and subsequently sold all 1,000 shares at $347.27, as part of a pre-arranged Rule 10b5-1 trading plan. This transaction, completed on June 25, 2026, converted equity awards into cash, leaving him with no directly held common shares but retaining 6,500 stock options expiring in 2035. The plan, adopted on February 23, 2026, has now terminated.
Krystal Biotech EVP sells $347,270 in common stock By Investing.com
Krystal Biotech's Executive Vice President and General Counsel, Thomas John Charles, sold 1,000 shares of common stock worth $347,270 on June 25, 2026, after exercising stock options. Following the sale, Mr. Thomas holds no direct shares but retains 6,500 derivative shares in stock options. The company recently exceeded Q1 2026 earnings expectations and received UK marketing authorization for its gene therapy VYJUVEK.
High Growth Tech Stocks In US For June 2026
Despite a recent market drop, the US market is up 19% over the past year, with expected annual earnings growth of 18%, making high-growth tech stocks an attractive investment. This article identifies top-performing tech companies like Five9, Vericel, and Krystal Biotech, highlighting their strong revenue and earnings growth, innovative solutions, and strategic market positioning. The report emphasizes the importance of these companies' adaptability and R&D efforts in a dynamic market.
High Growth Tech Stocks In US For June 2026
This article identifies top high-growth tech stocks in the US for June 2026, focusing on companies with strong revenue and earnings growth potential despite market fluctuations. It highlights Three companies—Five9, Vericel, and Krystal Biotech—detailing their operational strengths, recent achievements, and growth forecasts. The analysis is based on Simply Wall St's screener for US High Growth Tech and AI Stocks.
Krystal Biotech (KRYS) Rallies On Pipeline Optimism, Is The Stock Already Pricey?
Krystal Biotech (KRYS) has seen significant stock rallies, with a 46.7% return over the past three months, driven by pipeline optimism. Despite its current trading price of $359.93 making it appear overvalued by 11.5% according to one narrative, a discounted cash flow (DCF) model suggests a fair value of $794.48, indicating it might be undervalued based on long-term cash flow potential. Investors are encouraged to review underlying data and consider both risks and rewards.
KRYS (KRYS) option exercise: 1,000 shares to be sold on 06/25/2026
Krystal Biotech (KRYS) has filed a Form 144, reporting a stock option exercise and the planned sale of 1,000 shares of common stock on June 25, 2026. The filing also discloses a prior sale of 642 shares on May 26, 2026, which generated $193,903.26. These transactions were handled through Fidelity Brokerage Services LLC, with cash as the consideration method for the 1,000-share option exercise.
Krystal Biotech, Inc. Actuals & Estimates (MUN:4KB)
This article provides an overview of Krystal Biotech, Inc. (MUN:4KB) stock, including its current price, market capitalization, earnings, and analyst forecasts. It details financial actuals and estimates, highlighting recent performance, upcoming earnings dates, and key financial metrics like revenue, net income, and EBITDA. The stock has shown significant increases over the past year, and analysts provide a price target range.
Form 144 Krystal Biotech For: 25 June By Investing.com
This article from Investing.com reports on a Form 144 filing by Krystal Biotech for June 25th. The filing indicates insider intent to sell restricted stock. Krystal Biotech's stock symbol is KRYS, which showed a gain of +3.54%.
Krystal Biotech stock hits all-time high at 357.65 USD
Krystal Biotech (KRYS) stock reached an all-time high of $357.65, demonstrating significant investor confidence with a 148.74% one-year increase. The company also reported strong Q1 2026 earnings, surpassing expectations, and received UK marketing authorization for its gene therapy VYJUVEK. Despite an InvestingPro analysis indicating the stock is currently overvalued, these developments highlight the company's strong performance and expanding market presence in the biotech sector.
Price to book forward of Krystal Biotech, Inc. – SWB:4KB
The article presents financial data for Krystal Biotech, Inc. (SWB:4KB), specifically focusing on its price-to-book forward metric. It appears to be a financial snapshot from TradingView, displaying no current trade information and noting the market is closed. The content provided is largely navigational and descriptive of TradingView's platform features rather than in-depth analysis.
Enterprise value to revenue forward of Krystal Biotech, Inc. – NASDAQ:KRYS
The article provides information regarding the enterprise value to revenue forward for Krystal Biotech, Inc. (NASDAQ: KRYS). It appears to be a financial data page from TradingView, offering an overview, financials, news, and other data for the company. The content primarily focuses on presenting a financial metric within the platform's interface.
The Brown Capital Management Small Company Fund Bets on Krystal Biotech (KRYS) for Its Resilient Revenue Stream
The Brown Capital Management Small Company Fund has added Krystal Biotech (KRYS) to its portfolio, highlighting the company's resilient revenue stream. Krystal Biotech is a commercial-stage gene therapy company with an FDA-approved product, VYJUVEK, for dystrophic epidermolysis bullosa (DEB), and is expanding into other dermatologic and respiratory indications. The fund's investment thesis is based on continued market penetration, international expansion, and Krystal's broad pipeline, with expectations of significant annual revenue growth and high operating margins.
The Brown Capital Management Small Company Fund Bets on Krystal Biotech (KRYS) for Its Resilient Revenue Stream
The Brown Capital Management Small Company Fund has added Krystal Biotech (KRYS) to its portfolio, recognizing the company's strong revenue stream driven by its FDA-approved gene therapy, VYJUVEK, for dystrophic epidermolysis bullosa. Despite a challenging quarter for the fund, Krystal Biotech's near-monopolistic position in DEB and its platform-driven growth engine with high gross margins and expanding pipeline make it an attractive and recession-resistant investment. The fund anticipates continued penetration in the US market, expansion into Europe and Japan, and significant annual revenue growth for KRYS.
Krystal Biotech (KRYS) Is Up 7.2% After Institutional Ownership Surges To Sector-Leading Levels
Krystal Biotech (KRYS) has seen a significant 11.17% quarter-over-quarter increase in institutional ownership, reaching a sector-leading score of 10.00, driven by major investors like ETHSX and BlackRock. This surge in professional interest is linked to recent approvals of their drug VYJUVEK in Europe, Japan, and the UK, supporting a projected revenue of $1.0 billion and earnings of $568.7 million by 2029. Despite this optimism and a P/E ratio of 44.93, the company faces risks related to VYJUVEK concentration and treatment variability.
Krystal Biotech (KRYS) Is Up 7.2% After Institutional Ownership Surges To Sector-Leading Levels
Krystal Biotech (KRYS) has seen its institutional ownership surge to a sector-leading score of 10.00, with major investors like ETHSX and BlackRock increasing their holdings by 11.17% quarter-over-quarter. This heightened professional investor interest comes as the company's P/E ratio stands at 44.93 and its VYJUVEK gene therapy receives new approvals in Europe, Japan, and the UK, underpinning a growth story with projected strong revenue and earnings by 2029. Despite the optimism, the article highlights risks related to VYJUVEK concentration and treatment variability.
3 Biotech Firms With Major Potential Catalysts in the Coming Months
This article identifies three biotech firms, Vera Therapeutics (VERA), Krystal Biotech (KRYS), and ADMA Biologics (ADMA), that have significant potential catalysts in the near future. Vera and Krystal are clinical-stage companies awaiting key FDA decisions or data readouts for their promising drug candidates, while ADMA, an established firm with multiple products, has manufacturing efficiencies and an investigational candidate that could drive growth. Investors looking for opportunities in the biopharma sector might consider these companies, keeping an eye on their upcoming developments.
3 US Pharmaceutical Stocks With Strong Margins And Earnings Growth
This article examines how the US Section 301 investigation into Germany's pharmaceutical pricing could impact American drug companies. It highlights three US pharmaceutical stocks—Krystal Biotech (KRYS), Kiniksa Pharmaceuticals International (KNSA), and Gilead Sciences (GILD)—that appear well-positioned in this evolving trade landscape, detailing their operations, market caps, and the interaction of their strengths with potential challenges. The analysis emphasizes their strong margins and earnings growth prospects amidst trade policy shifts.
TD Cowen Maintains Krystal Biotech(KRYS.US) With Buy Rating, Raises Target Price to $403
TD Cowen has reiterated its Buy rating for Krystal Biotech (KRYS.US) and increased the price target to $403 from the previous $375. This update reflects the firm's continued confidence in the company's prospects.
Krystal Biotech (KRYS) Revenue Growth Puts VYJUVEK Pipeline Progress In Focus
Krystal Biotech (KRYS) is experiencing significant revenue growth and progress in its rare disease pipeline, particularly with VYJUVEK for dystrophic epidermolysis bullosa. The company's stock has seen substantial gains over the past year, attracting investor attention. While VYJUVEK remains a key revenue driver, investors are also focusing on the broader genetic therapy pipeline to mitigate concentration risk.
Krystal Biotech (KRYS) Revenue Growth Puts VYJUVEK Pipeline Progress In Focus
Krystal Biotech (KRYS) is experiencing strong revenue growth, with its stock up significantly over the past year, driven by the success of VYJUVEK for dystrophic epidermolysis bullosa and advancements in its rare disease pipeline. Investors are focusing on the sustainability of VYJUVEK's revenue growth, the progress of its earlier-stage genetic therapies, and how these factors will reduce the company's reliance on a single product. Despite positive analyst sentiment, execution risk and revenue volatility are noted as key concerns for the company.
Krystal Biotech stock hits all-time high at 332.33 USD By Investing.com
Krystal Biotech (KRYS) stock reached an all-time high of $332.33, with a market capitalization of $9.74 billion, reflecting a 147.56% increase over the past year. The company's strong performance is supported by a 94% gross profit margin and an "EXCELLENT" financial health score. This surge follows strong Q1 2026 results that exceeded earnings and revenue forecasts, and the marketing authorization of its gene therapy VYJUVEK in the UK for dystrophic epidermolysis bullosa.
Krystal Biotech Inc (KRYS) Institutional Confidence
Krystal Biotech Inc (KRYS) has an institutional shareholding score of 10.00, placing it first among 388 companies in the Biotechnology & Medical Research industry. Institutional ownership stands at 110.59%, an 11.17% increase quarter-over-quarter. Fidelity Management & Research Company LLC and BlackRock Institutional Trust Company, N.A. are among the largest institutional shareholders.
Krystal Biotech Inc (KRYS) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the shareholder structure of Krystal Biotech Inc (KRYS), identifying major individual and institutional holders. It provides a breakdown of shareholder types, institutional holdings over several quarters, and recent shareholder activity with changes in holdings for key investors. The report also lists various ETFs that include KRYS in their portfolios.
Krystal Biotech Inc (KRYS) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides an overview of Krystal Biotech Inc (KRYS) stock, focusing on its dividend and stock split history. It indicates that the company has not distributed any dividends over the past five years and has no recorded stock splits. The page also presents current stock data including market cap and P/E ratio.
Krystal Biotech Inc (KRYS) Valuation: PE, PB & Fair Value Analysis
Krystal Biotech Inc (KRYS) has a current valuation score of 7.41, placing it 241 out of 388 in the Biotechnology & Medical Research industry. Its P/E ratio stands at 44.11, significantly lower than its recent high but above its recent low. The article notes that relevant data for P/B, P/S, and P/CF ratios have not yet been disclosed by the company.
Krystal Biotech stock hits all-time high at 332.33 USD By Investing.com
Krystal Biotech Inc.'s stock reached an all-time high of $332.33, with a market capitalization of $9.74 billion, reflecting a 147.56% increase over the past year. The company's strong performance is supported by an impressive gross profit margin of 94% and excellent financial health. Recent achievements include exceeding Q1 2026 earnings and revenue forecasts, and receiving marketing authorization in the UK for its gene therapy VYJUVEK.
Krystal Biotech Jumps 5.8% Amid Sector-Wide Rally
Krystal Biotech (KRYS) saw its shares climb 5.8% to $342.16, participating in a broader rally across the biotechnology sector. The increase was observed alongside similar gains in other biotech companies, suggesting a renewed investor interest in the sector rather than specific company news. Krystal's market capitalization reached $10.1 billion, supported by positive recent analyst activity.
Krystal Biotech stock hits all-time high at 332.33 USD
Krystal Biotech Inc.'s stock reached an all-time high of 332.33 USD, reflecting a 147.56% increase over the past year and a market capitalization of $9.74 billion, driven by strong investor confidence and an "EXCELLENT" financial health score. The company recently reported exceeding Q1 2026 earnings and revenue forecasts, and its gene therapy VYJUVEK received marketing authorization in the UK. BofA Securities adjusted its price target slightly while maintaining a Buy rating.
Understanding the Setup: (KRYS) and Scalable Risk
This article analyzes Krystal Biotech Inc. (NASDAQ: KRYS), noting strong sentiment and an exceptional 32.7:1 risk-reward setup, targeting a 9.5% gain versus 0.3% risk. It outlines three AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—tailored for different risk profiles, and includes multi-timeframe signal analysis to support an overweight bias.
Krystal Biotech Inc (KRYS) Earnings Forecast: Future EPS & Revenue Growth Estimates
Krystal Biotech Inc (KRYS) has an earnings forecast score of 8.67, placing it 77th in its industry. Analysts have assigned a consensus "Buy" rating with an average target price of $218.00. The company's expected revenue for the next quarter is $125.62M, with anticipated EPS of $1.76.
Stocks Jump As Trump Touts Iran Deal: SiTime, Krystal Biotech, Howmet In Focus
The stock market saw indexes jump on June 11, 2026, following former President Trump's comments about an Iran deal. This report highlights the day's market action with Alissa Coram and Ken Shreve discussing key stocks such as SiTime, Krystal Biotech, and Howmet Aerospace. The article also features a variety of related videos covering market analysis, investment strategies, and industry insights.
Krystal Biotech stock hits all-time high at 319.6 USD
Krystal Biotech (KRYS) stock reached an all-time high of $319.60, currently trading at $318.08 with a market capitalization of $9.37 billion. The company has seen a 124% increase in its stock price over the past year, driven by strong gross profit margins of 94% and a healthy balance sheet. Recent positive news includes exceeding Q1 2026 earnings and revenue forecasts and receiving marketing authorization in the UK for its gene therapy, VYJUVEK.
Krystal Biotech stock hits all-time high at 319.6 USD
Krystal Biotech Inc. (KRYS) stock reached an all-time high of $319.60, representing a 124% increase over the past year. The company recently reported strong first-quarter 2026 earnings, surpassing revenue and EPS forecasts, and received marketing authorization in the UK for its gene therapy VYJUVEK. These achievements highlight Krystal Biotech's robust performance and promising pipeline in the biotech sector.
KRYS: Future Returns Will Reflect UK Approval And Mixed Execution Debate
Krystal Biotech's analyst price targets have seen modest adjustments, reflecting both optimism and caution among analysts. Bullish reports highlight confidence in current valuations and execution, while bearish views concern over-optimistic valuations and execution risks. The company’s gene therapy, VYJUVEK, is a key commercial driver, supported by recent UK marketing authorization and strong pipeline growth, with core valuation inputs remaining largely unchanged.
Cash per share of Krystal Biotech, Inc. – MUN:4KB
This article provides financial information for Krystal Biotech, Inc. (MUN:4KB), specifically focusing on its cash per share. The content appears to be a stub or a section within a larger financial data platform, indicating where to find financial metrics for the company on the Munich Stock Exchange.
This Insider Has Just Sold Shares In Krystal Biotech
Krystal Biotech's founder, Krish Krishnan, recently sold US$7.6m worth of stock, reducing their holding by 1.7%. This was the largest insider sale in the past year, occurring at a price close to the current share price. While the sale raises some caution, the company remains profitable and growing, and insiders still own a significant 10% of the company.
Krystal Biotech Insider Sold Shares Worth $7,702,984, According to a Recent SEC Filing
An insider at Krystal Biotech (NASDAQ: KRYS) has sold shares valued at $7,702,984, as detailed in a recent SEC filing. The company is a commercial-stage biotechnology firm focused on developing genetic medicines for diseases with high unmet needs, including its approved product VYJUVEK for dystrophic epidermolysis bullosa. This transaction follows other recent insider share sales from the company, as reported by MT Newswires.
Is Krystal Biotech, Inc. (KRYS) A Good Stock To Buy Now?
Krystal Biotech (KRYS) is presented as a strong investment due to its gene therapy platform for rare diseases, highlighted by its commercialized product VYJUVEK and a robust pipeline across multiple indications. The article emphasizes the potential for significant growth, recurring high-margin revenue, and an undervalued market perception of its long-term platform opportunity. Key catalysts include European pricing resolutions, new study data, and Phase 3 enrollment, with a target price of $407 in a base case and $523 in a bull case.
Krystal Biotech, Inc. Balance Sheet – XETR:4KB
Krystal Biotech, Inc.'s balance sheet for Q1 2026 shows total assets of 1.21 billion EUR, a 6.47% increase from Q4 2025. Total liabilities also rose by 7.00% to 104.07 million EUR in the first quarter of 2026. This article provides a snapshot of the company's financial position and trends.
Krystal Biotech, Inc. Cash Flow – XETR:4KB
This article provides key cash flow metrics for Krystal Biotech, Inc. (XETR:4KB). It highlights that the free cash flow for Q1 2026 was €63.39 million, while for 2025, it stood at €160.84 million with an operating cash flow of €171.02 million. The data is presented in EUR and includes historical cash flow activities from 2016 through 2025.
